BR112015032343A8 - uso de ligantes receptores sigma para a prevenção e tratamento de dor associada a cistite intersticial/síndrome de dor na bexiga (ic/bps) - Google Patents
uso de ligantes receptores sigma para a prevenção e tratamento de dor associada a cistite intersticial/síndrome de dor na bexiga (ic/bps)Info
- Publication number
- BR112015032343A8 BR112015032343A8 BR112015032343A BR112015032343A BR112015032343A8 BR 112015032343 A8 BR112015032343 A8 BR 112015032343A8 BR 112015032343 A BR112015032343 A BR 112015032343A BR 112015032343 A BR112015032343 A BR 112015032343A BR 112015032343 A8 BR112015032343 A8 BR 112015032343A8
- Authority
- BR
- Brazil
- Prior art keywords
- bps
- prevention
- interstitial cystitis
- treatment
- receptor ligands
- Prior art date
Links
- 208000005615 Interstitial Cystitis Diseases 0.000 title abstract 6
- 230000002265 prevention Effects 0.000 title abstract 2
- 239000003982 sigma receptor ligand Substances 0.000 title abstract 2
- 239000003446 ligand Substances 0.000 abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13382246.0A EP2818166A1 (en) | 2013-06-26 | 2013-06-26 | Use of sigma receptor ligands for the prevention and treatment of pain associated to interstitial cystitis/bladder pain syndrome (IC/BPS) |
| PCT/EP2014/063360 WO2014207024A1 (en) | 2013-06-26 | 2014-06-25 | Use of sigma receptor ligands for the prevention and treatment of pain associated to interstitial cystitis/bladder pain syndrome (ic/bps) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112015032343A2 BR112015032343A2 (pt) | 2017-09-26 |
| BR112015032343A8 true BR112015032343A8 (pt) | 2018-01-23 |
Family
ID=48700506
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015032343A BR112015032343A8 (pt) | 2013-06-26 | 2014-06-25 | uso de ligantes receptores sigma para a prevenção e tratamento de dor associada a cistite intersticial/síndrome de dor na bexiga (ic/bps) |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20160151377A1 (https=) |
| EP (2) | EP2818166A1 (https=) |
| JP (1) | JP2016523276A (https=) |
| KR (1) | KR20160023839A (https=) |
| CN (1) | CN105377257A (https=) |
| AR (1) | AR096709A1 (https=) |
| AU (1) | AU2014301220A1 (https=) |
| BR (1) | BR112015032343A8 (https=) |
| CA (1) | CA2916568A1 (https=) |
| HK (1) | HK1221656A1 (https=) |
| IL (1) | IL243362A0 (https=) |
| MA (1) | MA38711A1 (https=) |
| MX (1) | MX2015017761A (https=) |
| PH (1) | PH12015502815A1 (https=) |
| RU (1) | RU2016102149A (https=) |
| SG (1) | SG11201510408XA (https=) |
| TN (1) | TN2015000558A1 (https=) |
| TW (1) | TWI629984B (https=) |
| WO (1) | WO2014207024A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2116539A1 (en) | 2008-04-25 | 2009-11-11 | Laboratorios Del. Dr. Esteve, S.A. | 1-aryl-3-aminoalkoxy-pyrazoles as sigma ligands enhancing analgesic effects of opioids and attenuating the dependency thereof |
| EP2353591A1 (en) | 2010-02-04 | 2011-08-10 | Laboratorios Del. Dr. Esteve, S.A. | Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof |
| EP2353598A1 (en) | 2010-02-04 | 2011-08-10 | Laboratorios Del. Dr. Esteve, S.A. | Sigma ligands for use in the prevention and/or treatment of postoperative pain |
| EP2388005A1 (en) | 2010-05-21 | 2011-11-23 | Laboratorios Del. Dr. Esteve, S.A. | Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy |
| EP2415471A1 (en) | 2010-08-03 | 2012-02-08 | Laboratorios Del. Dr. Esteve, S.A. | Use of sigma ligands in opioid-induced hyperalgesia |
| EP2524694A1 (en) | 2011-05-19 | 2012-11-21 | Laboratorios Del. Dr. Esteve, S.A. | Use of sigma ligands in diabetes type-2 associated pain |
| WO2015091505A1 (en) * | 2013-12-17 | 2015-06-25 | Laboratorios Del Dr. Esteve, S.A. | Gabapentinoids and sigma receptor ligands combinations |
| TW201607538A (zh) | 2013-12-17 | 2016-03-01 | 以斯提夫博士實驗室股份有限公司 | 血清素－去甲腎上腺素再攝取抑制劑（ＳＮＲＩＳ）和σ受體配體組合物 |
| WO2020113094A1 (en) | 2018-11-30 | 2020-06-04 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
| KR20250116520A (ko) | 2024-01-25 | 2025-08-01 | 가톨릭대학교 산학협력단 | 칸나비디올을 유효성분으로 포함하는 방광 통증 증후군의 예방 또는 치료용 조성물 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE497765T1 (de) * | 2001-07-10 | 2011-02-15 | Astellas Pharma Inc | Pharmazeutische zusammensetzung enthaltend quinuclidin-3'-yl 1-phenyl-1,2,3,4,- tetrahydroisoquinolin-2-carboxylat zur behandlung der interstitiellen cystitis und/oder der abakteriellen prostatitis |
| CA2576144C (en) | 2004-08-27 | 2012-12-11 | Laboratorios Del Dr. Esteve, S.A. | Sigma receptor inhibitors |
| TWI356699B (en) * | 2004-11-10 | 2012-01-21 | Kissei Pharmaceutical | Agent for treating interstitial cystitis and agent |
| WO2007025613A2 (en) * | 2005-07-15 | 2007-03-08 | Laboratorios Del Dr. Esteve, S.A. | Use of compounds binding to the sigma receptor for the treatment of diabetes-associated pain |
| MX2008011016A (es) * | 2006-03-01 | 2008-09-08 | Esteve Labor Dr | Inhibidores de receptor sigma. |
| CN101395157A (zh) * | 2006-03-01 | 2009-03-25 | 伊斯特芬博士实验室有限公司 | 作为西格玛受体抑制剂的吡唑衍生物 |
| EP2116539A1 (en) * | 2008-04-25 | 2009-11-11 | Laboratorios Del. Dr. Esteve, S.A. | 1-aryl-3-aminoalkoxy-pyrazoles as sigma ligands enhancing analgesic effects of opioids and attenuating the dependency thereof |
| EP2113501A1 (en) * | 2008-04-25 | 2009-11-04 | Laboratorios Del. Dr. Esteve, S.A. | 5-Methyl-1-(naphthalen-2-YL)-1H-Pyrazoles useful as sigma receptor inhibitors |
| EP2353598A1 (en) * | 2010-02-04 | 2011-08-10 | Laboratorios Del. Dr. Esteve, S.A. | Sigma ligands for use in the prevention and/or treatment of postoperative pain |
| EP2353591A1 (en) * | 2010-02-04 | 2011-08-10 | Laboratorios Del. Dr. Esteve, S.A. | Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof |
| EP2460804A1 (en) * | 2010-12-03 | 2012-06-06 | Laboratorios Del Dr. Esteve, S.A. | 5-methyl-1-(naphthalen-2-yl)-1h-pyrazole derivatives and their use in potentiating the effect of opioid analgesics |
| EP2460519A1 (en) * | 2010-12-03 | 2012-06-06 | Laboratorios Del. Dr. Esteve, S.A. | Use of sigma ligands in bone cancer pain |
| AU2012256237B2 (en) * | 2011-05-13 | 2017-01-05 | Array Biopharma Inc. | Pyrrolidinyl urea and pyrrolidinyl thiourea compounds as TrkA kinase inhibitors |
| EP2524694A1 (en) * | 2011-05-19 | 2012-11-21 | Laboratorios Del. Dr. Esteve, S.A. | Use of sigma ligands in diabetes type-2 associated pain |
-
2013
- 2013-06-26 EP EP13382246.0A patent/EP2818166A1/en not_active Withdrawn
-
2014
- 2014-06-24 TW TW103121723A patent/TWI629984B/zh not_active IP Right Cessation
- 2014-06-24 AR ARP140102374A patent/AR096709A1/es unknown
- 2014-06-25 MA MA38711A patent/MA38711A1/fr unknown
- 2014-06-25 BR BR112015032343A patent/BR112015032343A8/pt not_active Application Discontinuation
- 2014-06-25 SG SG11201510408XA patent/SG11201510408XA/en unknown
- 2014-06-25 US US14/900,786 patent/US20160151377A1/en not_active Abandoned
- 2014-06-25 HK HK16109869.1A patent/HK1221656A1/zh unknown
- 2014-06-25 AU AU2014301220A patent/AU2014301220A1/en not_active Abandoned
- 2014-06-25 WO PCT/EP2014/063360 patent/WO2014207024A1/en not_active Ceased
- 2014-06-25 TN TN2015000558A patent/TN2015000558A1/en unknown
- 2014-06-25 CA CA2916568A patent/CA2916568A1/en not_active Abandoned
- 2014-06-25 JP JP2016522457A patent/JP2016523276A/ja active Pending
- 2014-06-25 EP EP14734099.6A patent/EP3013338A1/en not_active Withdrawn
- 2014-06-25 KR KR1020167001865A patent/KR20160023839A/ko not_active Withdrawn
- 2014-06-25 CN CN201480040098.1A patent/CN105377257A/zh active Pending
- 2014-06-25 RU RU2016102149A patent/RU2016102149A/ru not_active Application Discontinuation
- 2014-06-25 MX MX2015017761A patent/MX2015017761A/es unknown
-
2015
- 2015-12-17 PH PH12015502815A patent/PH12015502815A1/en unknown
- 2015-12-27 IL IL243362A patent/IL243362A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112015032343A2 (pt) | 2017-09-26 |
| IL243362A0 (en) | 2016-02-29 |
| TW201536295A (zh) | 2015-10-01 |
| SG11201510408XA (en) | 2016-01-28 |
| AU2014301220A1 (en) | 2016-02-18 |
| JP2016523276A (ja) | 2016-08-08 |
| TN2015000558A1 (en) | 2017-04-06 |
| MX2015017761A (es) | 2016-07-06 |
| PH12015502815A1 (en) | 2016-03-21 |
| WO2014207024A1 (en) | 2014-12-31 |
| RU2016102149A (ru) | 2017-08-02 |
| TWI629984B (zh) | 2018-07-21 |
| CA2916568A1 (en) | 2014-12-31 |
| US20160151377A1 (en) | 2016-06-02 |
| EP3013338A1 (en) | 2016-05-04 |
| CN105377257A (zh) | 2016-03-02 |
| HK1221656A1 (zh) | 2017-06-09 |
| MA38711A1 (fr) | 2017-12-29 |
| AR096709A1 (es) | 2016-01-27 |
| KR20160023839A (ko) | 2016-03-03 |
| RU2016102149A3 (https=) | 2018-05-25 |
| EP2818166A1 (en) | 2014-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112015032343A8 (pt) | uso de ligantes receptores sigma para a prevenção e tratamento de dor associada a cistite intersticial/síndrome de dor na bexiga (ic/bps) | |
| EA201691872A1 (ru) | Гетероциклические соединения для применения в лечении pi3k-гамма-опосредованных расстройств | |
| EA201691619A1 (ru) | Конденсированные гетероциклические соединения | |
| CL2016001715A1 (es) | Nuevos inhibidores de glutaminasa | |
| BR112017011972A2 (pt) | derivados de azabicicloctano como agonistas de fxr para uso no tratamento de doenças hepáticas e gastrintestinais | |
| NZ732511A (en) | Small molecule inhibitors of egfr and pi3k | |
| MX2016015181A (es) | Combinacion de un anticuerpo del receptor 4 de quimiocina anti-cc y un agonista de 4-1 bb para el tratamiento del cancer. | |
| BR112017009497A2 (pt) | polinucleotídeos de aadc para o tratamento da doença de parkinson | |
| JOP20150048B1 (ar) | جزيئات جسم مضاد لـ lag-3 واستخداماتها | |
| MX2017016134A (es) | Aril dihidro-2h-benzo[b][1,4]oxazina sulfonamida y compuestos relacionados para uso como agonistas de rory y el tratamiento de enfermedad. | |
| MX2018008105A (es) | Compuestos inhibidores de metaloenzima. | |
| TN2016000084A1 (en) | Nsaid and sigma receptor ligand combinations | |
| MX2016001446A (es) | Inhibidores de heterobicicloaril rorc2 y metodos de uso de los mismos. | |
| CL2016001076A1 (es) | (aza) piridopirazolopirimidinonas e indazolopirimidinonas como inhibidores de fibrinolosis. | |
| PH12016501095A1 (en) | Gabapentinoids and sigma receptor ligands combinations | |
| CL2015003343A1 (es) | Composición farmacéutica que comprende un agente terapéutico modificado en base a hemoglobina, para el tratamiento para tratar el cáncer, e imágenes de diagnóstico. | |
| MX382904B (es) | Combinaciones de fármacos para tratar mieloma múltiple. | |
| EA033446B1 (ru) | Гетероциклическое соединение для лечения дегенерации желтого пятна и/или болезни штаргардта | |
| EA201691567A1 (ru) | Способы лечения легких травм головного мозга | |
| EA201691108A1 (ru) | Хиназолин-thf-амины в качестве ингибиторов pde1 | |
| EA201691773A1 (ru) | Галогенированные хиназолин-thf-амины в качестве ингибиторов pde1 | |
| PH12016502244A1 (en) | Hsp70 modulators and methods for making and using the same | |
| EA201691335A1 (ru) | Гексагидрофуропирролы в качестве ингибиторов pde1 | |
| PH12017500910A1 (en) | Use of sigma receptor ligands in osteoarthritis | |
| MX2018002298A (es) | Metodos de uso de interleucina 10 para el tratamiento de enfermedades y trastornos. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
| B11E | Dismissal acc. art. 34 of ipl - requirements for examination incomplete | ||
| B11T | Dismissal of application maintained [chapter 11.20 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |